We designed highly selective non-peptide agonists for the δ-opioid receptor. On the basis of the "message-address" concept in this field and the accessory site hypothesis, a novel class of hetericycle-fused octahydroisoquinoline derivatives were synthesized. One of these compounds (4aS
*, 12aR
*)-4a-(3-hydroxyphenyl)-2-methyl-1, 2, 3, 4, 4a, 5, 12, 12a-octahydropyrido[3, 4-b]acridine, TAN-67 (2)] showed high selectivity for the δ-opioid receptor (K
i=1.12 nM) in guinea-pig cerebrum with a 2070-fold lower affinity for the μ-opioid receptor and a 1600-fold lower affinity for the К-opioid receptor. TAN-67 was a potent δ-opioid receptor agonist with an IC
50 value of 6.61 nM in the mouse vas deferens assay that was reversed by naltrindole (NTI) (K
e=0.21). Moreover, TAN-67 was shown to have antinociceptive activity following subcutaneous administration in the mouse acetic acid abdominal constriction assay that was antagonized by NTI (δ
1-and δ
2-antagonist) and 7-benzylidinenaltrexone (δ
1-antagonist), but not by naltriben (δ
2-antagonist). This systemically applicable non-peptide agonist will be useful for elucidating the pharmacological properties of the δ-opioid receptor.
抄録全体を表示